LSE · IXI.L
IXICO plc
£0.12£0.00 (0.0%)
IXICO plc’s quoted price sits in the upper half of its reported 52-week range, 9.62% below the high.
Loading market information…
LSE · VRCI.L · GBp
Stock price, earnings
Quote as of Oct 30, 2026, 09:54 AM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
Verici Dx plc’s quoted price sits in the lower half of its reported 52-week range, 78.55% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Verici Dx plc’s next earnings report is currently expected on Jul 5, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Verici Dx plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Verici Dx plc is an immuno-diagnostics company primarily focused on the kidney transplantation sector. The firm specializes in creating both predictive and diagnostic assays for patients who have undergone kidney transplants. Its development pipeline features Clarava, a pre-transplant tool designed to forecast the likelihood of early acute rejection; Tuteva, a post-transplant assessment focusing on acute cellular rejection; and Protega, an innovative liquid biopsy aiming to predict the risk of fibrosis and eventual graft failure. Established in 2020, Verici Dx plc maintains its headquarters in Penarth, United Kingdom.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£0.12£0.00 (0.0%)
IXICO plc’s quoted price sits in the upper half of its reported 52-week range, 9.62% below the high.
£0.09-£0.01 (-5.56%)
Abingdon Health Plc’s quoted price sits in the lower half of its reported 52-week range, 34.62% below the high.
£0.01-£0.00 (-1.03%)
Genedrive Plc’s quoted price sits in the lower half of its reported 52-week range, 37.74% below the high.
£0.02+£0.00 (+0.71%)
Genflow Biosciences Plc’s quoted price sits in the lower half of its reported 52-week range, 40.93% below the high.
£0.01-£0.00 (-3.2%)
CelLBxHealth plc’s quoted price sits in the lower half of its reported 52-week range, 78.39% below the high.
£0.02+£0.00 (+15.75%)
Proteome Sciences plc’s quoted price sits in the lower half of its reported 52-week range, 61.59% below the high.
£0.06-£0.00 (-1.72%)
OptiBiotix Health Plc’s quoted price sits in the lower half of its reported 52-week range, 36.67% below the high.
£0.01+£0.00 (+1.52%)
GENinCode plc’s quoted price sits in the lower half of its reported 52-week range, 86.33% below the high.
